03/07/23 6:00 AMNasdaq : AXNX conferencesAxonics to Participate in the SUFU 2023 Winter MeetingAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is participating as a platinum sponsor of the Society of Urodynamics, Female Pelvic Medicine& Urogenital Reconstruction 2023 Winter Meeting, which is being held in Nashville from March 7-11.RHEA-AIneutral
03/01/23 4:01 PMNasdaq : AXNX earningsAxonics Reports Fourth Quarter and Fiscal Year 2022 Financial ResultsAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2022. “This quarter’ s record results reflect the growing demand for our best-in-class incontinence products,”...RHEA-AIneutral
02/08/23 4:30 PMNasdaq : AXNX conferencesearningsAxonics to Report Fourth Quarter 2022 Financial Results on March 1Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results.RHEA-AIneutral
01/31/23 6:00 AMNasdaq : AXNX fda approvalAxonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation SystemAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved the company’ s fourth-generation rechargeable sacral neuromodulation system. Axonics plans to commercially launch the...RHEA-AIneutral
01/11/23 6:00 AMNasdaq : AXNX earningsAxonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue GuidanceAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fiscal year ended December 31, 2022 and issued fiscal year 2023 revenue guidance. “This quarter’ s record revenue result reflects the growing...RHEA-AIvery positive
12/21/22 6:00 AMNasdaq : AXNX conferencesAxonics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Axonics is scheduled to present at 4:30 p.m. Pacific Time on Wednesday, January 11. A live webcast and...RHEA-AIneutral
12/13/22 6:00 AMNasdaq : AXNX Axonics Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation SystemAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Health Canada has approved the company’ s fourth-generation rechargeable sacral neuromodulation system. “Since Axonics’ founding, delivering superior patient experiences has...RHEA-AIvery positive
11/18/22 6:00 AMNasdaq : AXNX conferencesAxonics® to Participate in the Piper Sandler Healthcare ConferenceAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the Piper Sandler Healthcare Conference on December 1, 2022. Axonics is scheduled to present at 11:00 a.m. Eastern Time. Axonics recently ranked No. 1 on the 2022 Financial Times...RHEA-AIneutral
11/16/22 11:06 AMNasdaq : AXNX Axonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North AmericaAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 4 on the Deloitte Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North...RHEA-AIpositive
10/31/22 4:01 PMNasdaq : AXNX earningsAxonics® Reports Third Quarter 2022 Financial ResultsAxonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2022. “This quarter’ s record revenue result reflects growing demand from physicians and their patients for our best-in-class...RHEA-AIneutral